Once per cycle combination of long-acting hematopoietic growth factors (HGFs) pegfilgrastim and darbepoetin alfa (Peg-G + DPO) to reduce multi-lineage hematopoietic toxicity of chemotherapy with doxorubicin and ifosfamide (AI) in patients with sarcoma

Vadhan‐Raj, Saroj; Trent, J.; Burgess, M. A.; Patel, Sachin; Collard, M; Zachariah, Gracy; Hangoc, Giao; Johnson, Michael W.; He, Ben; Benjamin, Robert S.

doi:10.1200/jco.2005.23.16_suppl.8225

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vadhan-Raj and her colleagues confirmed the safety and the usefulness of pegilgrastim in preventing febrile neutropenia in patients with sarcoma receiving doxorubicin and ifosfamide. 36 In a novel study design, these investigators elected to combine once per chemotherapy cycle of pegfilgrastim and darbepoetin alfa in an attempt to reduce multi-lineage hematopoietic toxicity of the chemotherapy.…”

Section: Seriousness Of Neutropeniamentioning

confidence: 99%

Current and future use of hematopoietic growth factors in cancer medicine

Mughal

2004

Hematological Oncology

View full text Add to dashboard Cite

Myelosuppression, in particular neutropenia and anemia are serious complications of malignancy and its treatment. Neutropenia can make patients vulnerable to potentially life-threatening infection. It often results in dose reductions and delay of planned chemotherapy, which can have a significant detrimental effect on tumour response and survival. Anemia can be associated with a range of debilitating effects, which can severely impair patients' QOL. In addition, there is some evidence recognizing anemia as a poor prognostic indicator, associated with reduced treatment efficacy. Reduction in the duration and severity of neutropenia and anemia is possible by initiation of appropriate growth factors during the first and subsequent cycles of chemotherapy. New and improved growth factor support with agents such as pegfilgrastim and darbepoetin alfa has the potential to improve the management of chemotherapy-induced neutropenia and anemia further. Thrombopoietin is currently in clinical trials to assess its potential role in the treatment of thrombocytopenia in patients with cancer.

show abstract

Section: Seriousness Of Neutropeniamentioning

confidence: 99%

Current and future use of hematopoietic growth factors in cancer medicine

Mughal

2004

Hematological Oncology

View full text Add to dashboard Cite

show abstract

Once per cycle combination of long-acting hematopoietic growth factors (HGFs) pegfilgrastim and darbepoetin alfa (Peg-G + DPO) to reduce multi-lineage hematopoietic toxicity of chemotherapy with doxorubicin and ifosfamide (AI) in patients with sarcoma

Cited by 1 publication

References 0 publications

Current and future use of hematopoietic growth factors in cancer medicine

Current and future use of hematopoietic growth factors in cancer medicine

Contact Info

Product

Resources

About